A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR) - AVANZAR

AstraZeneca AB0 个研究点目标入组 1,000 人开始时间: 2022年8月23日最近更新: 2024年6月24日

研究概览

暂无简介。

•Participants = 18 years at screening
•Participants with stage IIIB or IIIC, histologically or cytologically documented NSCLC, not amenable for surgical resection or definitive chemoradiation, who have not received prior chemotherapy or other systemic therapy for first-line Stage IIIB, IIIC or IV NSCLC
•Lacks sensitising EGFR tumour tissue mutation and ALK and ROS1 rearrangements and has no documented tumour genomic alterations in NTRK, BRAF, RET, MET or other actionable driver oncogenes with approved therapies (actionable genomic alterations).
•ECOG PS of 0 or 1
•Archival tumour tissue collected prior to signing of ICF
•Has adequate bone marrow reserve and organ function within 7 days before randomisation
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 450
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 550

•Mixed small-cell lung cancer and NSCLC histology; sarcomatoid variant of NSCLC
•Persistent toxicities caused by previous anti-cancer therapy not yet improved to Grade = 1 or baseline
•Spinal cord compression or brain metastases
•History of leptomeningeal carcinomatosis.
•Known active or uncontrolled hepatitis B or C virus infection.
•Clinically significant corneal disease
•History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening

发起方